Gain Therapeutics (GANX) announced a poster presentation was made at the Society for Neuroscience annual meeting, Neuroscience 2025, held November 15th-19th in San Diego, CA. The poster outlined new evidence from three preclinical models supporting the Company’s lead drug candidate’s, GT-02287, proposed mechanism of action of facilitating trafficking of glucocerebrosidase to the mitochondria as well as the lysosomes, supporting its potential as a disease-modifying therapy for Parkinson’s disease. Data shows: GT-02287 reduces mitochondrial stress and enhances neuronal survival in MPP+ treated rat dopaminergic neurons; GT-02287 decreases staining for MIRO1, suggesting improved mitochondrial health in alpha-synuclein-induced mouse PD model ; GT-02287 improves mitochondrial function by facilitating GCase trafficking to the mitochondria in patient-derived fibroblasts harboring GBA1 mutation
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GANX:
- Positive Outlook for Gain Therapeutics: Promising Clinical Trial Results and Stable Financial Health Drive Buy Rating
- Promising Developments in Gain Therapeutics’ Parkinson’s Treatment Drive Buy Rating
- Gain Therapeutics Reports Continued Progress Amid Financial Challenges
- Gain Therapeutics reports Q3 EPS (15c), consensus (15c)
- Gain Therapeutics, Inc. (GANX) Q3 Earnings Cheat Sheet